
|Videos|February 8, 2016
Will Biosimilars Reduce Specialty Drug Spending?
Author(s)Davy James, Managing Editor
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Advertisement
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Closing the Calcium Gap: How Pharmacists Can Guide Patients Toward Better Bone Health
2
COVID-19 Vaccination in Medically Complex Adults
3
The Vaccine Schedule Just Changed Again—Here’s What's Real and What Isn't
4
Testing categories in practice — clinical conversations
5






































































































